Mon panier

DNA

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
BI-836858BI-836858Phase 2 ClinicalC.H. Boehringer Sohn Ag & Co. KgMyelodysplastic Syndromes; Leukemia, Myeloid, Acute
Details
CART-33 (Chinese PLA General Hospital)Phase 2 ClinicalPla General HospitalLeukemia, Myeloid; Leukemia, Myeloid, Acute
Details
Lintuzumab Ac-225 (Actinium Pharmaceuticals)225Ac-HuM-195; HuM195-Ac-225; AC225-MOAB-M195Phase 2 ClinicalPdl Biopharma IncMultiple Myeloma; Leukemia, Myeloid, Acute
Details
VBP-301VBP301; VBP-301Phase 2 ClinicalVor Biopharma IncLeukemia, Myeloid, Acute
Details
VBP-101VBP101; VBP-101Phase 2 ClinicalVor Biopharma IncMyelodysplastic Syndromes; Leukemia, Myeloid, Acute
Details
VCAR-33 (Vor Biopharma)VCAR-33; VCAR33Phase 2 ClinicalVor Biopharma IncLeukemia, Myeloid, Acute
Details
MP0533MP0533Phase 2 ClinicalMolecular Partners AgLeukemia, Myeloid, Acute
Details
CD33 CAR T Cells(Beijing Boren Hospital)Phase 2 ClinicalBeijing Gao Boren Hospital Co LtdLeukemia; Neoplasms; Leukemia, Myeloid, Acute
Details
EmerfetamabAMG-673; AMG673Phase 1 ClinicalAmgen IncLeukemia, Myeloid, Acute
Details
ICG-136ICG-136; 123b-33bcCARPhase 1 ClinicalIcell Gene Therapeutics (Int'L) LtdLeukemia, Myeloid, Acute
Details
VixtimotamabT-564; AMV-564Phase 1 ClinicalAmphivena Therapeutics IncSolid tumours; Myelodysplastic Syndromes
Details
AL-003AL-003Phase 1 ClinicalAbbvie Inc, Alector IncAlzheimer Disease
Details
PRGN-3006PRGN-3006Phase 1 ClinicalPrecigen IncMyelodysplastic Syndromes; Leukemia, Myeloid, Acute
Details
IM73 chimeric antigen receptor T cell therapyIM-73-CAR-TPhase 1 ClinicalBeijing Immunochina Medical Science & Technology Co LtdLeukemia, Myeloid, Acute
Details
ORM-6151ORM-6151Phase 1 ClinicalOrum Therapeutics IncMyelodysplastic Syndromes; Leukemia, Myeloid, Acute
Details
SENTI-202SENTI-202Phase 1 ClinicalSenti Biosciences IncHematologic Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute
Details
JNJ-67571244JNJ-67571244; JNJ-67371244; JNJ-1244Phase 1 ClinicalJohnson & JohnsonMyelodysplastic Syndromes; Leukemia, Myeloid, Acute
Details
CD33-NKECD33-NKE; CD33 NKEPhase 1 ClinicalBristol-Myers Squibb CompanyLeukemia, Myeloid, Acute
Details
Optimised CD33 (FL-33) CAR T Therapy(Beijing GoBroad Hospital)Phase 1 ClinicalBeijing GoBroad HospitalLeukemia, Myeloid, Acute
Details
Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute)Phase 1 ClinicalShenzhen Geno-Immune Medical InstituteLeukemia, Myeloid, Acute
Details
CD33/CLL1 dual CAR-NK cell therapy(Institute Of Hematology & Blood Diseases Hospital)Phase 1 ClinicalInstitute Of Hematology & Blood Diseases Hospital, Hangzhou Qihan Biotechnology Co LtdNeoplasm, Residual; Leukemia, Myeloid, Acute
Details
CD33 CAR-NK cell therapy(Institute Of Hematology & Blood Diseases Hospital)Phase 1 ClinicalInstitute Of Hematology & Blood Diseases Hospital, Hangzhou Qihan Biotechnology Co LtdNeoplasm, Residual; Leukemia, Myeloid, Acute
Details
IMGN-779IMGN-779Phase 1 ClinicalImmunogen IncLeukemia, Myeloid, Acute
Details
EluvixtamabMT-114; AMG-330Phase 1 ClinicalAmgen IncMyelodysplastic Syndromes; Leukemia, Myeloid, Acute
Details
IBR-733IBR-733; IBR733Phase 1 ClinicalImbioray (Hangzhou) Biomedicine Co LtdLeukemia, Myeloid, Acute
Details
CD33 CAR-T Therapy (Zhejiang University)Phase 1 ClinicalZhejiang UniversityLeukemia, Myeloid, Acute
Details
CLL1+CD33 CAR-T(Zhejiang University)Phase 1 ClinicalZhejiang UniversityLeukemia, Myeloid, Acute
Details
anti-CD33 CAR T cells therapy(iCell Gene Therapeutics)Phase 1 ClinicalIcell Gene Therapeutics (Int'L) LtdHematologic Neoplasms; Leukemia, Myeloid, Acute
Details
Anti-CD33/CLL1 CAR-NK Cell TherapyPhase 1 ClinicalImbioray (Hangzhou) Biomedicine Co LtdLeukemia, Myeloid, Acute
Details
Lintuzumab Ac-225/VenetoclaxPhase 1 ClinicalActinium Pharmaceuticals IncLeukemia, Promyelocytic, Acute
Details
DXC-007(Hangzhou Dac Biotech Company)DXC-007Phase 1 ClinicalHangzhou Dac Biotech Company LtdLeukemia; Leukemia, Myeloid, Acute
Details
Lintuzumab-gelonin conjugatePhase 1 ClinicalThe University Of Texas MD Anderson Cancer CenterLeukemia, Myelogenous, Chronic; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute
Details
Anti-CD33/CLL-1 CAR-T (Legend)Phase 1 ClinicalLegend Biotech CorpLeukemia, Promyelocytic, Acute
Details
Anti-CD33/anti-FcgammaRI bispecific antibody (UCSD)Phase 1 ClinicalUniversity Of California San DiegoLeukemia, Myeloid, Acute
Details
Anti-CD33 CAR T cell therapy (Wuhan Bio-Raid)ClinicalWuhan BioRaid Biotechnology Co LtdLeukemia, Myeloid, Acute
Details

Informations sur les médicaments commercialisés

Nom anglaisCode de recherchePhase de R&DEntreprisePlus ancien nom de marquePays d'approbation le plus ancienIndication la plus ancienneSociété d'approbation la plus ancienneDate d'approbation la plus ancienneIndicationEssai clinique
Gemtuzumab ozogamicinCMA-676; CDP-771; WAY-CMA-676; CL-555201; hP67.6-calicheamicinApprovedUcb Sa, Pfizer IncMylotargJapanLeukemia, Myeloid, AcutePfizer Inc2008-01-18Leukemia; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Juvenile; Leukemia, Lymphocytic, Chronic, B-Cell
Details
  • Liste de produits
  • Informations sur les médicaments commercialisés
  • Informations sur les médicaments cliniques